Animal Models for Target Diseases in Gene Therapy — using DNA and siRNA Delivery Strategies

被引:0
|
作者
Ian S. Blagbrough
Chiara Zara
机构
[1] University of Bath,Department of Pharmacy and Pharmacology
来源
Pharmaceutical Research | 2009年 / 26卷
关键词
efficacy; gene delivery; pharmacodynamics; pharmacokinetics; RNAi;
D O I
暂无
中图分类号
学科分类号
摘要
Nanoparticles, including lipopolyamines leading to lipoplexes, liposomes, and polyplexes are targeted drug carrier systems in the current search for a successful delivery system for polynucleic acids. This review is focused on the impact of gene and siRNA delivery for studies of efficacy, pharmacodynamics, and pharmacokinetics within the setting of the wide variety of in vivo animal models now used. This critical appraisal of the recent literature sets out the different models that are currently being investigated to bridge from studies in cell lines through towards clinical reality. Whilst many scientists will be familiar with rodent (murine, fecine, cricetine, and musteline) models, few probably think of fish as a clinically relevant animal model, but zebrafish, madake, and rainbow trout are all being used. Larger animal models include rabbit, cat, dog, and cow. Pig is used both for the prevention of foot-and-mouth disease and human diseases, sheep is a model for corneal transplantation, and the horse naturally develops arthritis. Non-human primate models (macaque, common marmoset, owl monkey) are used for preclinical gene vector safety and efficacy trials to bridge the gap prior to clinical studies. We aim for the safe development of clinically effective delivery systems for DNA and RNAi technologies.
引用
收藏
相关论文
共 50 条
  • [1] Animal Models for Target Diseases in Gene Therapy - using DNA and siRNA Delivery Strategies
    Blagbrough, Ian S.
    Zara, Chiara
    PHARMACEUTICAL RESEARCH, 2009, 26 (01) : 1 - 18
  • [2] In utero gene therapy for genetic disease: animal models, target diseases and ethical considertions
    Coutelle, C
    GENE THERAPY, 2004, 11 : S143 - S143
  • [3] Combination of gene therapy strategies in animal models of ovarian cancer
    Kuiper, M
    Sanches, R
    DIncan, C
    Monceau, S
    Pradeyrol, C
    Bignon, YJ
    CANCER GENE THERAPY, 1997, 4 (05) : 319 - 319
  • [4] siRNA in ovarian cancer - Delivery strategies and targets for therapy
    van den Brand, Dirk
    Mertens, Vicky
    Massuger, Leon F. A. G.
    Brock, Roland
    JOURNAL OF CONTROLLED RELEASE, 2018, 283 : 45 - 58
  • [5] Delivery Strategies of siRNA Therapeutics for Hair Loss Therapy
    Jin, Su-Eon
    Sung, Jong-Hyuk
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (14)
  • [6] Gene Therapy in Large Animal Models of Human Genetic Diseases Introduction
    Wolfe, John H.
    ILAR JOURNAL, 2009, 50 (02) : 107 - 111
  • [7] Gene therapy for lysosomal storage diseases: the lessons and promise of animal models
    Ellinwood, NM
    Vite, CH
    Haskins, ME
    JOURNAL OF GENE MEDICINE, 2004, 6 (05): : 481 - 506
  • [8] Gene Therapy for Lysosomal Storage Diseases (LSDs) in Large Animal Models
    Haskins, Mark
    ILAR JOURNAL, 2009, 50 (02) : 112 - 121
  • [9] Gene delivery to large animal models using AAV vectors
    Chamberlain, J.
    Seto, J.
    Ramos, J.
    Hauschka, S.
    Odom, G.
    NEUROMUSCULAR DISORDERS, 2015, 25 : S290 - S290
  • [10] Direct Gene Therapy for Bone Regeneration: Gene Delivery, Animal Models, and Outcome Measures
    Pelled, Gadi
    Ben-Arav, Ayelet
    Hock, Colleen
    Reynolds, David G.
    Yazici, Cemal
    Zilberman, Yoram
    Gazit, Zulma
    Awad, Hani
    Gazit, Dan
    Schwarz, Edward M.
    TISSUE ENGINEERING PART B-REVIEWS, 2010, 16 (01) : 13 - 20